Tinlarebant

A medication used to treat geographic atrophy secondary to age-related macular degeneration

Tinlarebant is a medication used in the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). It is classified as a retinol binding protein 4 (RBP4) antagonist, which plays a role in the visual cycle by inhibiting the transport of retinol to the retina.

Mechanism of Action

Tinlarebant works by inhibiting the activity of RBP4, a protein responsible for the transport of retinol (vitamin A) from the liver to the retina. By blocking this transport, tinlarebant reduces the accumulation of toxic byproducts in the retina, which are implicated in the progression of geographic atrophy. This mechanism helps to slow down the degeneration of retinal cells and preserve vision in patients with AMD.

Clinical Use

Tinlarebant is specifically indicated for patients with geographic atrophy secondary to age-related macular degeneration. Geographic atrophy is an advanced form of AMD characterized by the progressive loss of retinal cells, leading to vision impairment. Tinlarebant is administered orally and is part of a treatment regimen aimed at slowing the progression of this condition.

Side Effects

Common side effects of tinlarebant may include mild gastrointestinal disturbances, such as nausea and diarrhea. As with any medication, there is a potential for allergic reactions, and patients are advised to report any unusual symptoms to their healthcare provider.

Research and Development

Tinlarebant is the result of extensive research into the pathophysiology of age-related macular degeneration and the role of the visual cycle in retinal health. Ongoing clinical trials continue to evaluate its efficacy and safety in larger populations and over extended periods.

Related pages

• Age-related macular degeneration
• Retinol binding protein 4
• Geographic atrophy

Chemical structure of Tinlarebant